New study tracks immune risk in rare bone disease drug
NCT ID NCT05234567
First seen Feb 16, 2026 · Last updated May 24, 2026 · Updated 18 times
Summary
This study follows 30 people with hypophosphatasia (HPP) who are taking the medication asfotase alfa. Researchers want to see if the body's immune system can make the drug less effective or cause serious allergic reactions. Participants will be observed for at least 5 years to track these risks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPOPHOSPHATASIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinical Trial Site
RECRUITINGHartford, Connecticut, 06106, United States
-
Clinical Trial Site
RECRUITINGChicago, Illinois, 60611, United States
-
Clinical Trial Site
RECRUITINGBoston, Massachusetts, 02122, United States
-
Clinical Trial Site
RECRUITINGKansas City, Missouri, 64108, United States
-
Clinical Trial Site
RECRUITINGMineola, New York, 11501, United States
-
Clinical Trial Site
NOT_YET_RECRUITINGCincinnati, Ohio, 45229, United States
-
Clinical Trial Site
RECRUITINGColumbus, Ohio, 43203, United States
-
Clinical Trial Site
NOT_YET_RECRUITINGPittsburgh, Pennsylvania, 15224, United States
-
Clinical Trial Site
RECRUITINGNashville, Tennessee, 37112, United States
-
Clinical Trial Site
RECRUITINGSalt Lake City, Utah, 84108, United States
-
Clinical Trial Site
RECRUITINGCharlottesville, Virginia, 22903, United States
-
Clinical Trial Site
RECRUITINGMadison, Wisconsin, 53792, United States
Conditions
Explore the condition pages connected to this study.